Loading...

News List

由Mirati Therapeutics研发的口服KRAS G12C抑制剂adagrasib(MRTX849)上市

2022-12-15


由Mirati Therapeutics研发的口服KRAS G12C抑制剂adagrasib(MRTX849)上市

2022.12.12,美国FDA 宣布,批准由Mirati Therapeutics研发的口服KRAS G12C抑制剂adagrasib(MRTX849)上市,用于治疗至少接受过一种先前全身性疗法的KRAS G12C突变非小细胞肺癌(NSCLC)患者。这是继Lumakras(sotorasib)之后全球上市的第2款KRAS G12C抑制剂。2021年6月,该产品获FDA授予突破性疗法资格认定。安进的sotorasib是全球首个上市的KRAS G12C抑制剂,2021年5月获批用于二线治疗KRAS G12C突变的晚期或转移性NSCLC患者。

Pre: New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Next: adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.